Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT ID: NCT01285609

Last Updated: 2020-06-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1289 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-16

Study Completion Date

2017-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to compare Overall Survival (OS) of participants with Stage IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin, and have received at least one dose of blinded study therapy (ipilimumab or placebo).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer - Non Small Cell Squamous

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ipilimumab + Paclitaxel and Carboplatin

Ipilimumab + Active Chemo Backbone

Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)

Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses

Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses

Group Type EXPERIMENTAL

Ipilimumab

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Placebo + Paclitaxel and Carboplatin

Placebo + Active Chemo Backbone

Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)

Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses

Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ipilimumab

Intervention Type DRUG

Placebo

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMS-734016 Taxol® Paraplatin®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non small cell lung cancer (NSCLC) - squamous cell
* Stage IV or recurrent NSCLC
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria

* Brain Metastases
* Autoimmune diseases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution

Porto, , Portugal

Site Status

Local Institution

Santa Maria da Feira, , Portugal

Site Status

Local Institution

Vila Nova de Gaia, , Portugal

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Bucharest, , Romania

Site Status

Local Institution

Cluj-Napoca, , Romania

Site Status

Local Institution

Sibiu, , Romania

Site Status

Local Institution

Suceava, , Romania

Site Status

Local Institution

Timișoara, , Romania

Site Status

Local Institution

Chelyabinsk, , Russia

Site Status

Local Institution

Kazan', , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Moscow, , Russia

Site Status

Local Institution

Pyatigorsk, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

Saint Petersburg, , Russia

Site Status

Local Institution

St-Peterburg, , Russia

Site Status

Local Institution

Tula, , Russia

Site Status

Local Institution

Singapore, , Singapore

Site Status

Local Institution

Vereeniging, Gauteng, South Africa

Site Status

Local Institution

Gyeonggi-do, , South Korea

Site Status

Local Institution

Panorama,cape Town, Western Cape, South Africa

Site Status

Local Institution

Cape Town, , South Africa

Site Status

Local Institution

Durban, , South Africa

Site Status

Local Institution

Goyang-si, Gyeonggi-do, South Korea

Site Status

Local Institution

Suwon, Gyeonggi-do, South Korea

Site Status

Local Institution

Seoul, Kangnam-gu, South Korea

Site Status

Local Institution

Cheonju-si, North Chungcheong, South Korea

Site Status

Local Institution

Seoul, Seodaemungu, South Korea

Site Status

Local Institution

Busan, , South Korea

Site Status

Sharp Memorial Hospital

San Diego, California, United States

Site Status

Va Connecticut Healthcare System

West Haven, Connecticut, United States

Site Status

Lynn Cancer Institute Center For Hematology-Oncology

Boca Raton, Florida, United States

Site Status

Integrated Community Oncology Network

Jacksonville, Florida, United States

Site Status

University Of Illinois At Chicago Medical Center

Chicago, Illinois, United States

Site Status

Quincy Medical Group

Quincy, Illinois, United States

Site Status

Presence Medical Group Hematology Oncology

Skokie, Illinois, United States

Site Status

Southern Illinois University School Of Medicine

Springfield, Illinois, United States

Site Status

St. Francis Hospital & Health Centers

Indianapolis, Indiana, United States

Site Status

Floyd Memorial Cancer Center Of Indiana

New Albany, Indiana, United States

Site Status

Kentucky Cancer Clinic

Hazard, Kentucky, United States

Site Status

Norton Cancer Institute

Louisville, Kentucky, United States

Site Status

Montgomery Cancer Center

Mount Sterling, Kentucky, United States

Site Status

St Joseph Mercy Hospital

Ypsilanti, Michigan, United States

Site Status

University Of Kansas Cancer Center

Kansas City, Missouri, United States

Site Status

Washington University School Of Medicine

St Louis, Missouri, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Clinical Research Alliance, Inc.

Lake Success, New York, United States

Site Status

Durham Va Medical Center (111g)

Durham, North Carolina, United States

Site Status

Carolina Biooncology Institute

Huntersville, North Carolina, United States

Site Status

Novant Health Oncology Specialists

Lexington, North Carolina, United States

Site Status

Gabrail Cancer Center Research

Canton, Ohio, United States

Site Status

Oklahoma Oncology And Hematology, Pc Dba

Tulsa, Oklahoma, United States

Site Status

Kaiser Permanente Northwest Region

Portland, Oregon, United States

Site Status

Guthrie Medical Group, P.C.

Sayre, Pennsylvania, United States

Site Status

Wjb Dorn Va Medical Center

Columbia, South Carolina, United States

Site Status

Cancer Center Of The Carolinas

Greenville, South Carolina, United States

Site Status

Associated in Oncology and Hematology

Chattanooga, Tennessee, United States

Site Status

Tennessee Cancer Specialists

Knoxville, Tennessee, United States

Site Status

Thompson Oncology Group

Knoxville, Tennessee, United States

Site Status

Texas Oncology, PA - South Austin Cancer Center

Austin, Texas, United States

Site Status

Blue Ridge Cancer Care

Blacksburg, Virginia, United States

Site Status

Local Institution

Daegu, , South Korea

Site Status

Wisconsin Institutes for Medical Research

Madison, Wisconsin, United States

Site Status

Local Institution

Quilmes, Buenos Aires, Argentina

Site Status

Local Institution

Rosario, Santa Fe Province, Argentina

Site Status

Local Institution

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Local Institution

Córdoba, , Argentina

Site Status

Local Institution

Córdoba, , Argentina

Site Status

Local Institution

Mendoza, , Argentina

Site Status

Local Institution

Santa Fe, , Argentina

Site Status

Local Institution

Bedford Park, South Australia, Australia

Site Status

Local Institution

Box Hill, Victoria, Australia

Site Status

Local Institution

Frankston, Victoria, Australia

Site Status

Local Institution

Heidelberg, Victoria, Australia

Site Status

Local Institution

Wodonga, Victoria, Australia

Site Status

Local Institution

Graz, , Austria

Site Status

Local Institution

Linz, , Austria

Site Status

Local Institution

Salzburg, , Austria

Site Status

Local Institution

Aalst, , Belgium

Site Status

Local Institution

Liège, , Belgium

Site Status

Local Institution

Sint-Niklaas, , Belgium

Site Status

Local Institution

Yvoir, , Belgium

Site Status

Local Institution

Fortaleza, Ceará, Brazil

Site Status

Local Institution

Belo Horizonte, Minas Gerais, Brazil

Site Status

Local Institution

Curitiba, Paraná, Brazil

Site Status

Local Institution

Passo Fundo, Rio Grande do Sul, Brazil

Site Status

Local Institution

Barretos, São Paulo, Brazil

Site Status

Local Institution

São José dos Campos, São Paulo, Brazil

Site Status

Local Institution

Porto Alegre, , Brazil

Site Status

Local Institution

Ribeirão Preto, , Brazil

Site Status

Local Institution

Rio de Janeiro, , Brazil

Site Status

Local Institution

São Paulo, , Brazil

Site Status

Local Institution

São Paulo, , Brazil

Site Status

Local Institution

Montreal, Quebec, Canada

Site Status

Local Institution

Montreal, Quebec, Canada

Site Status

Local Institution

Montreal, Quebec, Canada

Site Status

Local Institution

Oshawa, , Canada

Site Status

Local Institution

Viña del Mar, Región de Valparaíso, Chile

Site Status

Local Institution

Santiago, Santiago Metropolitan, Chile

Site Status

Local Institution

Santiago, Santiago Metropolitan, Chile

Site Status

Local Institution

Guangzhou, Guangdong, China

Site Status

Local Institution

Guanzhou, Guangdong, China

Site Status

Local Institution

Shantou, Guangdong, China

Site Status

Local Institution

Wuhan, Hubei, China

Site Status

Local Institution

Nanjing, Jiangsu, China

Site Status

Local Institution

Nanjing, Jiangsu, China

Site Status

Local Institution

Suzhou, Jiangsu, China

Site Status

Local Institution

Changchun, Jilin, China

Site Status

Local Institution

Xi'an, Shaanxi, China

Site Status

Local Institution

Xi'an, Shaanxi, China

Site Status

Local Institution

Ürümqi, Xinjiang, China

Site Status

Local Institution

Hangzhou, Zhejiang, China

Site Status

Local Institution

Beijing, , China

Site Status

Local Institution

Beijing, , China

Site Status

Local Institution

Beijing, , China

Site Status

Local Institution

Beijing, , China

Site Status

Local Institution

Santiago, , China

Site Status

Local Institution

Shanghai, , China

Site Status

Local Institution

Shanghai, , China

Site Status

Local Institution

Montería, Departamento de Córdoba, Colombia

Site Status

Local Institution

Pereira, Risaralda Department, Colombia

Site Status

Local Institution

Ostrava, Poruba, Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Prague, , Czechia

Site Status

Local Institution

Pribram V-Zdabor, , Czechia

Site Status

Local Institution

Ústí nad Labem, , Czechia

Site Status

Local Institution

Znojmo, , Czechia

Site Status

Local Institution

Aalborg, , Denmark

Site Status

Local Institution

Herlev, , Denmark

Site Status

Local Institution

Hillerød, , Denmark

Site Status

Local Institution

Næstved, , Denmark

Site Status

Local Institution

Odense, , Denmark

Site Status

Local Institution

Caen, , France

Site Status

Local Institution

Marseille, , France

Site Status

Local Institution

Paris, , France

Site Status

Local Institution

Poitiers, , France

Site Status

Local Institution

Rennes, , France

Site Status

Local Institution

Toulouse, , France

Site Status

Local Institution

Vandœuvre-lès-Nancy, , France

Site Status

Local Institution

Bad Berka, , Germany

Site Status

Local Institution

Bochum, , Germany

Site Status

Local Institution

Darmstadt, , Germany

Site Status

Local Institution

Dresden, , Germany

Site Status

Local Institution

Frankfurt am Main, , Germany

Site Status

Local Institution

Gauting, , Germany

Site Status

Local Institution

Grosshandsdorf, , Germany

Site Status

Local Institution

Hamburg, , Germany

Site Status

Local Institution

Heidelberg, , Germany

Site Status

Local Institution

Kassel, , Germany

Site Status

Local Institution

Lübeck, , Germany

Site Status

Local Institution

Mainz, , Germany

Site Status

Local Institution

München, , Germany

Site Status

Local Institution

Neumünster, , Germany

Site Status

Local Institution

Nuremberg, , Germany

Site Status

Local Institution

Regensburg, , Germany

Site Status

Local Institution

Tübingen, , Germany

Site Status

Local Institution

Ulm, , Germany

Site Status

Local Institution

Villingen-Schwenningen, , Germany

Site Status

Local Institution

Hong Kong, , Hong Kong

Site Status

Local Institution

Hong Kong, , Hong Kong

Site Status

Local Institution

New Territories, , Hong Kong

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Budapest, , Hungary

Site Status

Local Institution

Deszk, , Hungary

Site Status

Local Institution

Farkasgyepű, , Hungary

Site Status

Local Institution

Gyula, , Hungary

Site Status

Local Institution

Mátraháza, , Hungary

Site Status

Local Institution

Nyíregyháza, , Hungary

Site Status

Local Institution

Pécs, , Hungary

Site Status

Local Institution

Sopron, , Hungary

Site Status

Local Institution

Székesfehérvár, , Hungary

Site Status

Local Institution

Szolnok, , Hungary

Site Status

Local Institution

Dublin, , Ireland

Site Status

Local Institution

Dublin, , Ireland

Site Status

Local Institution

Dublin, , Ireland

Site Status

Local Institution

Galway, , Ireland

Site Status

Local Institution

Beersheba, , Israel

Site Status

Local Institution

Haifa, , Israel

Site Status

Local Institution

Jerusalem, , Israel

Site Status

Local Institution

Nahariya, , Israel

Site Status

Local Institution

Petah Tikva, , Israel

Site Status

Local Institution

Rehovot, , Israel

Site Status

Local Institution

Tel Aviv, , Israel

Site Status

Local Institution

Tel Aviv, , Israel

Site Status

Local Institution

Tel Litwinsky, , Israel

Site Status

Local Institution

Ẕerifin, , Israel

Site Status

Local Institution

Benevento, , Italy

Site Status

Local Institution

Bologna, , Italy

Site Status

Local Institution

Lido di Camaiore, , Italy

Site Status

Local Institution

Lucca, , Italy

Site Status

Local Institution

Monza, , Italy

Site Status

Local Institution

Padua, , Italy

Site Status

Local Institution

Perugia, , Italy

Site Status

Local Institution

Siena, , Italy

Site Status

Local Institution

Sondrio, , Italy

Site Status

Local Institution

Terni, , Italy

Site Status

Local Institution

Treviglio, , Italy

Site Status

Local Institution

Nagoya, Aichi-ken, Japan

Site Status

Local Institution

Nagoya, Aichi-ken, Japan

Site Status

Local Institution

Kashiwa, Chiba, Japan

Site Status

Local Institution

Kanazawa, Ishikawa-ken, Japan

Site Status

Local Institution

Yokohama, Kanagawa, Japan

Site Status

Local Institution

Yokohama, Kanagawa, Japan

Site Status

Local Institution

Natori-shi, Miyagi, Japan

Site Status

Local Institution

Sendai, Miyagi, Japan

Site Status

Local Institution

Kurashiki-shi, Okayama-ken, Japan

Site Status

Local Institution

Kurashiki-shi, Okayama-ken, Japan

Site Status

Local Institution

Hirakata-shi, Osaka, Japan

Site Status

Local Institution

Osaka, Osaka, Japan

Site Status

Local Institution

Sunto-gun, Shizuoka, Japan

Site Status

Local Institution

Chuo-ku, Tokyo, Japan

Site Status

Local Institution

Ube-shi, Yamaguchi, Japan

Site Status

Local Institution

Akashi, Hyogo, , Japan

Site Status

Local Institution

Fukuoka, , Japan

Site Status

Local Institution

Matsuyama, Ehime, , Japan

Site Status

Local Institution

Sapporo Hokkaido, , Japan

Site Status

Local Institution

Sapporo, Hokkaido, , Japan

Site Status

Local Institution

Sayama, , Japan

Site Status

Local Institution

Sendai, Miyagi, , Japan

Site Status

Local Institution

Takatsuki, , Japan

Site Status

Local Institution

Tokyo, , Japan

Site Status

Local Institution

Zapopan, Jalisco, Mexico

Site Status

Local Institution

Mexico City, Mexico City, Mexico

Site Status

Local Institution

Monterrey, Nuevo León, Mexico

Site Status

Local Institution

's-Hertogenbosch, , Netherlands

Site Status

Local Institution

Breda, , Netherlands

Site Status

Local Institution

Harderwijk, , Netherlands

Site Status

Local Institution

Nieuwegein, , Netherlands

Site Status

Local Institution

Trujillo, La Libertad, Peru

Site Status

Local Institution

Arequipa, , Peru

Site Status

Local Institution

Cercado, , Peru

Site Status

Local Institution

Lima, , Peru

Site Status

Local Institution

Elblag, , Poland

Site Status

Local Institution

Gdansk, , Poland

Site Status

Local Institution

Gdansk- Zaspa, , Poland

Site Status

Local Institution

Grudziądz, , Poland

Site Status

Local Institution

Olsztyn, , Poland

Site Status

Local Institution

Otwock, , Poland

Site Status

Local Institution

Poznan, , Poland

Site Status

Local Institution

Szczecin, , Poland

Site Status

Local Institution

Torun, , Poland

Site Status

Local Institution

Warsaw, , Poland

Site Status

Local Institution

São Martinho do Bispo, Coimbra District, Portugal

Site Status

Local Institution

Lisbon, , Portugal

Site Status

Local Institution

Lisbon, , Portugal

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Seoul, , South Korea

Site Status

Local Institution

Suwon, , South Korea

Site Status

Local Institution

Barakaldo, Vizcaya, Spain

Site Status

Local Institution

Ávila, , Spain

Site Status

Local Institution

Benidorm-alicante, , Spain

Site Status

Local Institution

Castellon, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Madrid, , Spain

Site Status

Local Institution

Manresa, , Spain

Site Status

Local Institution

Ourense, , Spain

Site Status

Local Institution

Valencia, , Spain

Site Status

Local Institution

Valencia, , Spain

Site Status

Local Institution

Gothenburg, , Sweden

Site Status

Local Institution

Lund, , Sweden

Site Status

Local Institution

Stockholm, , Sweden

Site Status

Local Institution

Umeå, , Sweden

Site Status

Local Institution

Basel, , Switzerland

Site Status

Local Institution

Winterthur, , Switzerland

Site Status

Local Institution

Changhua, , Taiwan

Site Status

Local Institution

Chiayi City, , Taiwan

Site Status

Local Institution

Kaohsiung County, , Taiwan

Site Status

Local Institution

Taichung, , Taiwan

Site Status

Local Institution

Taichung, , Taiwan

Site Status

Local Institution

Taipei, , Taiwan

Site Status

Local Institution

Taipei, , Taiwan

Site Status

Local Institution

Taipei, , Taiwan

Site Status

Local Institution

Bangkok, Tungpayathai, Thailand

Site Status

Local Institution

Bangkok, , Thailand

Site Status

Local Institution

Bangkok, , Thailand

Site Status

Local Institution

Bangkok, , Thailand

Site Status

Local Institution

Chiang Mai, , Thailand

Site Status

Local Institution

Songkhla, , Thailand

Site Status

Local Institution

Dundee, Angus/forfarshire, United Kingdom

Site Status

Local Institution

Truro, Cornwall, United Kingdom

Site Status

Local Institution

Southampton, Hampshire, United Kingdom

Site Status

Local Institution

Nottingham, , United Kingdom

Site Status

Local Institution

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Chile China Colombia Czechia Denmark France Germany Hong Kong Hungary Ireland Israel Italy Japan Mexico Netherlands Peru Poland Portugal Romania Russia Singapore South Africa South Korea Spain Sweden Switzerland Taiwan Thailand United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-017396-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CA184-104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.